Payment overview · 2025
General Payments
$3,761.86
245 reported records · 27 companies
Healthcare provider profile · identity verified
Steven Michael Samuels, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREENWOOD, IN · NPI 1205806387
Verified facts
What the public records show
CMS Open Payments records show Steven Michael Samuels, MD received $3,761.86 in general payments during 2025 across 245 reported records.
HARMONY BIOSCIENCES LLC accounted for 11.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 56 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 416 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $426.16 | 11.3% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $336.42 | 8.9% | 26 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $329.29 | 8.8% | 25 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $319.01 | 8.5% | 20 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $302.96 | 8.1% | 37 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $265.19 | 7.0% | 29 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $252.53 | 6.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $232.23 | 6.2% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $218.36 | 5.8% | 17 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $190.42 | 5.1% | 12 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $185.25 | 4.9% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $168.24 | 4.5% | 14 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $99.24 | 2.6% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $56.49 | 1.5% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $56.37 | 1.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.27 | 1.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $39.11 | 1.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.73 | 0.9% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $34.47 | 0.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.67 | 0.8% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $27.23 | 0.7% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.51 | 0.6% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $18.26 | 0.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.40 | 0.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.68 | 0.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.93 | 0.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.44 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,761.86 | 245 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $426.16 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $234.09 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $232.27 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $232.23 | 14 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $228.13 | 29 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $190.42 | 12 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $185.25 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $174.17 | 15 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $137.54 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $136.42 | 10 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $131.35 | 17 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $119.31 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.77 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $112.45 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $112.45 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $99.24 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $96.07 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $87.81 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $86.74 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $84.80 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $84.80 | 8 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $70.13 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $68.95 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.42 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $61.90 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $61.90 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $61.90 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $59.71 | 8 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $58.07 | 7 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $56.49 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $56.37 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $49.94 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.54 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $34.47 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $34.47 | 2 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $27.23 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $23.04 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.17 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $20.11 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $19.80 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.95 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.19 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $10.47 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $7.95 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $7.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 246 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 90 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 30 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 235 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 416 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 230 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
132 | 41 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
90 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
235 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
230 | 75 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
235 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
416 | 81 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
246 | 73 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2123 | 596 |
| Gabapentin | Gabapentin | 1388 | 432 |
| Losartan Potassium | Losartan Potassium | 1328 | 374 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1278 | 319 |
| Omeprazole | Omeprazole | 1045 | 308 |
| Amlodipine Besylate | Amlodipine Besylate | 983 | 296 |
| Metoprolol Succinate | Metoprolol Succinate | 880 | 264 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 771 | 230 |
| Lisinopril | Lisinopril | 763 | 219 |
| Metformin Hcl | Metformin Hcl | 699 | 206 |
| Carvedilol | Carvedilol | 670 | 183 |
| Duloxetine Hcl | Duloxetine Hcl | 511 | 149 |
| Tamsulosin Hcl | Tamsulosin Hcl | 502 | 147 |
| Torsemide | Torsemide | 456 | 153 |
| Mounjaro | Tirzepatide | 416 | 81 |
| Prednisone | Prednisone | 416 | 295 |
| Pantoprazole Sodium | Pantoprazole Sodium | 412 | 121 |
| Simvastatin | Simvastatin | 409 | 110 |
| Hydrochlorothiazide | Hydrochlorothiazide | 381 | 108 |
| Spironolactone | Spironolactone | 371 | 119 |
| Trazodone Hcl | Trazodone Hcl | 369 | 118 |
| Sertraline Hcl | Sertraline Hcl | 347 | 104 |
| Allopurinol | Allopurinol | 312 | 87 |
| Buspirone Hcl | Buspirone Hcl | 311 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 306 | 89 |
| Meloxicam | Meloxicam | 285 | 95 |
| Alendronate Sodium | Alendronate Sodium | 283 | 85 |
| Dexamethasone | Dexamethasone | 282 | 245 |
| Ezetimibe | Ezetimibe | 273 | 90 |
| Pravastatin Sodium | Pravastatin Sodium | 264 | 69 |
| Diclofenac Sodium | Diclofenac Sodium | 257 | 101 |
| Eliquis | Apixaban | 246 | 73 |
| Glimepiride | Glimepiride | 244 | 76 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 242 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 237 | 87 |
| Jardiance | Empagliflozin | 235 | 62 |
| Montelukast Sodium | Montelukast Sodium | 233 | 67 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 230 | 75 |
| Citalopram Hbr | Citalopram Hydrobromide | 226 | 67 |
| Doxazosin Mesylate | Doxazosin Mesylate | 219 | 57 |
| Doxycycline Hyclate | Doxycycline Hyclate | 213 | 187 |
| Famotidine | Famotidine | 206 | 65 |
| Fluoxetine Hcl | Fluoxetine Hcl | 206 | 73 |
| Valsartan | Valsartan | 199 | 57 |
| Celecoxib | Celecoxib | 191 | 90 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 187 | 61 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 177 | 50 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 174 | 150 |
| Clopidogrel | Clopidogrel Bisulfate | 174 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 170 | 48 |
| Furosemide | Furosemide | 160 | 51 |
| Mirtazapine | Mirtazapine | 159 | 47 |
| Finasteride | Finasteride | 149 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 144 | 46 |
| Levofloxacin | Levofloxacin | 136 | 119 |
| Synthroid | Levothyroxine Sodium | 132 | 41 |
| Potassium Chloride | Potassium Chloride | 130 | 35 |
| Tramadol Hcl | Tramadol Hcl | 126 | 35 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 125 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 124 | 36 |
| Xarelto | Rivaroxaban | 121 | 26 |
| Atenolol | Atenolol | 118 | 33 |
| Cephalexin | Cephalexin | 115 | 81 |
| Azithromycin | Azithromycin | 114 | 102 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 108 | 88 |
| Donepezil Hcl | Donepezil Hcl | 107 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 105 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 104 | 31 |
| Ondansetron Odt | Ondansetron | 103 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 32 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 98 | 61 |
| Ozempic | Semaglutide | 97 | 21 |
| Colesevelam Hcl | Colesevelam Hcl | 95 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 95 | 76 |
| Meclizine Hcl | Meclizine Hcl | 94 | 54 |
| Farxiga | Dapagliflozin Propanediol | 90 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 86 | 26 |
| Myrbetriq | Mirabegron | 86 | 26 |
| Bupropion Hcl Sr | Bupropion Hcl | 85 | 34 |
| Lamotrigine | Lamotrigine | 83 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 76 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 21 |
| Clonidine Hcl | Clonidine Hcl | 69 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 26 |
| Naproxen | Naproxen | 68 | 19 |
| Bupropion Xl | Bupropion Hcl | 63 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 61 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 20 |
| Topiramate | Topiramate | 55 | 14 |
| Trulicity | Dulaglutide | 55 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 52 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 14 |
| Baclofen | Baclofen | 51 | 13 |
| Fluconazole | Fluconazole | 51 | 43 |
| Linzess | Linaclotide | 50 | suppressed |
| Lovastatin | Lovastatin | 49 | 14 |
| Irbesartan | Irbesartan | 48 | 13 |
| Metformin Hcl Er | Metformin Hcl | 48 | 17 |
| Alprazolam | Alprazolam | 47 | 12 |
| Cefuroxime | Cefuroxime Axetil | 47 | 45 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 16 |
| Valacyclovir | Valacyclovir Hcl | 45 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 14 |
| Acyclovir | Acyclovir | 42 | 11 |
| Olanzapine | Olanzapine | 42 | suppressed |
| Glipizide | Glipizide | 41 | 13 |
| Lansoprazole | Lansoprazole | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 11 |
| Klor-Con M20 | Potassium Chloride | 39 | 16 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 38 | 33 |
| Amoxicillin | Amoxicillin | 37 | 24 |
| Humalog Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Ramipril | Ramipril | 37 | suppressed |
| Tradjenta | Linagliptin | 37 | 12 |
| Memantine Hcl | Memantine Hcl | 36 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Gemtesa | Vibegron | 30 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Lamotrigine Er | Lamotrigine | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | 11 |
| Folic Acid | Folic Acid | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,761.86 · 245 records | HARMONY BIOSCIENCES LLC | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, Bimzelx, CAPLYTA, COMIRNATY, COSENTYX, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, Fluad, Flucelvax, GEMTESA, GVOKE HYPOPEN, JARDIANCE, KISUNLA, LINZESS, LUMRYZ, MOUNJARO, NEXLETOL, NUCALA, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, REPATHA, REXULTI, RINVOQ, Rybelsus, SHINGRIX, SKYRIZI, Sunosi, TALTZ, TEZSPIRE, TRELEGY ELLIPTA, Tymlos, Tyvaso, UBRELVY, UPLIZNA, VIBERZI, VRAYLAR, VYNDAMAX, VYNDAQEL, Veozah, WAKIX, Wegovy, XYWAV, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error